In the pivotal CREST clinical trial, sasanlimab in combination with Bacillus Calmette-Guérin met the primary endpoint of ...

Imagine what we could do if we could take that time and replace it with a single login to a centralized, one stop shop system ...

Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or ...

Xofluza (baloxavir marboxil) met its primary endpoint in the CENTERSTONE trial, reducing the odds of untreated household ...

Brensocatib significantly reduced the rate of pulmonary exacerbations and slowed lung function decline in patients with ...

Lorundrostat, a selective aldosterone synthase inhibitor, significantly reduced systolic blood pressure in patients with ...

In this video interview, Rob Jones, product manager, TMF practice area, Pharmalex, talks AI and how change is needed for the ...

In addition to meeting the primary endpoint of superior A1C reduction, the once-daily oral pill reduced weight by an average ...

In the Phase III SELECT-GCA trial, Rinvoq (upadacitinib) 15 mg with a 26-week glucocorticoid taper significantly improved ...

Cobenfy (xanomeline and trospium chloride) as an adjunctive treatment to atypical antipsychotics demonstrated a 2.0-point ...

In this video interview, Rob Jones, product manager, TMF practice area, Pharmalex, highlights recent ICH guidelines and how ...

Tolebrutinib did not show superiority over Aubagio (teriflunomide) in reducing relapse rates or MRI-detected inflammatory ...